Abstract
Primary non-Hodgkin’s lymphoma (NHL) of the thyroid gland is a rare disease with an incidence of 0.5 per 100,000 population. Stages IE and IIE thyroid NHL have been traditionally treated by surgical resection; however, modern treatment consists of chemotherapy and local radiotherapy, and surgery is often reserved for tissue diagnosis and relief of airway compression. We retrospectively reviewed the management and outcomes of nine consecutive patients with thyroid NHL, eight females and one male (median age 63 yr, range 34-71 yr) treated between 1994 and 1999. Five patients had disease stage IE and 4 stage IIE. Median follow-up was 72 mo. Pathohistology and immunohistochemistry identified two patients with mucosa-associated lymphoid tissue (MALT), three follicular center cell lymphoma (FCC), two patients large B-cell lymphoma (BLCL), one a marginal zone lymphoma (MZL), and one patient a peripheral T-cell lymphoma (PTCL). Total thyroidectomy was performed in three patients and subtotal thyroidectomy in four. One (MALT) patient underwent surgery alone; three patients surgery, radiotherapy, and chemotherapy (two FCC, one PTCL); three patients surgery and chemotherapy (one MALT, one FCC, one LBCL); and two chemotherapy alone (one LBCL, one MZL). Median survival was 79 mo (range 13–124 mo). The PTCL patient, a 34-yr-old man, died from disseminated disease at 13 mo despite secondary chemotherapy, and one LBCL patient with extensively invasive local disease died from stroke 17 mo after diagnosis. The remaining seven patients remain in remission with no local or systemic relapse at a mean of 86 mo. With appropriate therapy primary thyroid NHL has a favorable course; however, prognosis depends on the histology, local spread, and the stage of the disease at presentation, as well as the patient’s performance status. Surgery in combination with chemotherapy and/or radiotherapy is still warranted for intermediate and high-grade thyroid NHLs, with over 77% of patients achieving long-term remission. Peripheral T-cell lymphoma carries a poor prognosis.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Derringer GA, Thompson LD, Frommelt RA, Bijwaard KE, Heffess CS, Abbondanzo SL. Malignant lymphoma of the thyroid gland: a clinicopathologic study of 108 cases.Am J Surg Pathol 2000;24(5):623–639.
Klyachkin ML, et al. Thyroid lymphoma: is there a role for surgery?Am Surg 1998;64(3):234–238.
Doria R, Jekel JF, Cooper DL. Thyroid lymphoma. The case for combined modality therapy.Cancer 1994;73 (1):200–206.
Wirtzfeld DA, Winston JS, Hicks WL Jr, Loree TR. Clinical presentation and treatment of non-Hodgkin’s lymphoma of the thyroid gland.Ann Surg Oncol 2001;8(4):338–341.
Lam KY, Lo CY, Kwong DL, Lee J, Srivastava G. Malignant lymphoma of the thyroid. A 30-year clinicopathologic experience and an evaluation of the presence of Epstein-Barr virus.Am J Clin Pathol 1999;112(2):263–270.
DiBiase SJ, Grigsby PW, Guo C, Lin HS, Wasserman TH. Outcome analysis for stage IE and IIE thyroid lymphoma.Am J Clin Oncol 2004;27(2);178–184.
Hyjek E, Isaacson PG. Primary B cell lymphoma of the thyroid and its relationship to Hashimoto’s thyroiditis.Hum Pathol 1988;19(11):1315–1326.
Blair TJ, Evans RG, Buskirk SJ, Banks PM, Earle JD. Radiotherapeutic management of primary thyroid lymphoma.Int J Radiat Oncol Biol Phys 1985;11(2):365–370.
Burke JS, Butler JJ, Fuller LM. Malignant lymphomas of the thyroid: a clinical pathologic study of 35 patients including ultrastructural observations.Cancer 1977;39(4):1587–1602.
Sasai K, et al. Non-Hodgkin’s lymphoma of the thyroid. A clinical study of twenty-two cases.Acta Oncol 1996;35(4):457–462.
Junor EJ, Paul J, Reed NS. Primary non-Hodgkin’s lymphoma of the thyroid.Eur J Surg Oncol 1992;18(4):313–321.
Laing RW, et al. The significance of MALT histology in thyroid lymphomas: a review of patients from the BNLI and Royal Marsden Hospital.Clin Oncol (R Coll Radiol) 1994;6(5):300–304.
Logue JP, Hale RJ, Stewart AL, Duthie MB, Banerjee SS. Primary malignant lymphoma of the thyroid: a clinicopathological analysis.Int J Radiat Oncol Biol Phys 1992;22(5):929–933.
Tupchong L, Hughes F, Harmer CL. Primary lymphoma of the thyroid: clinical features, prognostic factors, and results of treatment.Int J Radiat Oncol Biol Phys 1986;12(10):1813–1821.
Motoi N, Ozawa Y. Malignant T-cell lymphoma of the thyroid gland associated with Hashimoto’s thyroiditis.Pathol Int 2005;55(7):425–430.
Sirota DK, Segal RL. Primary lymphomas of the thyroid gland.JAMA 1979;242(16):1743–1746.
Tsang RW, Gospodarowicz MK, Sutcliffe SB, Sturgeon JF, Panzarella T, Patterson BJ. Non-Hodgkin’s lymphoma of the thyroid gland: prognostic factors and treatment outcome. The Princess Margaret Hospital Lymphoma Group.Int J Radiat Oncol Biol Phys 1993;27(3):599–604.
Shimkin PM, Sagerman RH. Lymphoma of the thyroid gland.Radiology 1969;92(4):812–816.
Cabanillas F, Bodey GP, Freireich EJ. Management with chemotherapy only of stage I and II malignant lymphoma of aggressive histologic types.Cancer 1980;46(11) 2356–2359.
Vigliotti A, Kong JS, Fuller LM, Velasquez WS. Thyroid lymphomas stage IE and IIE: comparative results for radiotherapy only, combination chemotherapy only, and multimodality treatment.Int J Radiat Oncol Biol Phys 1986;12(10):1807–1812.
Holm LE, Blomgren H, Lowhagen T. Cancer risks in patients with chronic lymphocytic thyroiditis.N Engl J Med 1985;312(10):601–604.
Tobinai K, et al. Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma.Ann Oncol 2004;15(5):821–830.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Čolović, M., Matić, S., Kryeziu, E. et al. Outcomes of primary thyroid non-Hodgkin’s Lymphoma. Med Oncol 24, 203–208 (2007). https://doi.org/10.1007/BF02698041
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02698041